Skip to main content
SpringerLink
Log in

Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Inhibitors of phosphodiesterase 10A (PDE10A), an enzyme highly expressed in medium spiny neurons of the mammalian striatum, enhance activity in direct (dopamine D1 receptor-expressing) and indirect (D2 receptor-expressing striatal output) pathways. The ability of such agents to act to potentiate D1 receptor signaling while inhibiting D2 receptor signaling suggest that PDE10A inhibitors may have a unique antipsychotic-like behavioral profile differentiated from the D2 receptor antagonist-specific antipsychotics currently used in the treatment of schizophrenia.

Objectives

To evaluate the functional consequences of PDE10A inhibitor modulation of D1 and D2 receptor pathway signaling, we compared the effects of a PDE10A inhibitor (TP-10) on D1 and D2 receptor agonist-induced disruptions in prepulse inhibition (PPI), a measure of sensorimotor gating disrupted in patients with schizophrenia.

Results

Our results indicate that, in rats: (1) PDE10A inhibition (TP-10, 0.32–10.0 mg/kg) has no effect on PPI disruption resulting from the mixed D1/D2 receptor agonist apomorphine (0.5 mg/kg), confirming previous report; (2) Yet, TP-10 blocked the PPI disruption induced by the D2 receptor agonist quinpirole (0.5 mg/kg); and attenuated apomorphine-induced disruptions in PPI in the presence of the D1 receptor antagonist SCH23390 (0.005 mg/kg).

Conclusions

These findings indicate that TP-10 cannot block dopamine agonist-induced deficits in PPI in the presence of D1 activation and suggest that the effect of PDE10A inhibition on D1 signaling may be counterproductive in some models of antipsychotic activity. These findings, and the contribution of TP-10 effects in the direct pathway on sensorimotor gating in particular, may have implications for the potential antipsychotic efficacy of PDE10A inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Agid O, Kapur S, Remington G (2008) Emerging drugs for schizophrenia. Expert Opin Emerg Drugs 13:479–495

    Article  CAS  PubMed  Google Scholar 

  • Bleickardt C, LaShomb A, Jones N, Mullins D, Uslaner J, Vardigan J et al. (2010) Characterization of the selective PDE10 inhibitor, SCH 1518291, in rodent models predictive of antipsychotic efficacy. Program Number 665.15. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010. Online

  • Bortolato M, Aru GN, Fà M, Frau R, Orrù M, Salis P et al (2005) Activation of D1, but not D2 receptors potentiates dizocilpine-mediated disruption of prepulse inhibition of the startle. Neuropsychopharmacology 30:561–574

    Article  CAS  PubMed  Google Scholar 

  • Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patients groups, and pharmacological studies. Psychopharmacology 156:234–258

    Article  CAS  PubMed  Google Scholar 

  • Bubenikova-Valesova V, Svoboda J, Horacek J, Vales K (2009) The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats. Int J Neuropsychopharmacol 12:873–883

    Article  CAS  PubMed  Google Scholar 

  • Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annu Rev Pharmacol Toxicol 41:237–260

    Article  CAS  PubMed  Google Scholar 

  • Chang WL, Weber M, Breier MR, Saint Marie RL, Hines SR, Swerdlow NR (2012) Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats. Brain Res 1437:69–76

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chappie T, Humphrey J, Menniti F, Schmidt C (2009) PDE10A inhibitors: an assessment of the current CNS drug discovery landscape. Curr Opin Drug Discov Dev 12:458–467

    CAS  Google Scholar 

  • DeMartinis NA (2012) Results of a phase 2a proof-of-concept trial with a PDE10A inhibitor in the treatment of acute exacerbation of schizophrenia. Session 16, Presentation Number 62. 2012 Meeting Planner. Philadelphia, PA: Society of Biological Psychiatry, 2012. Online

  • Ellenbroek BA, Budde S, Cools AR (1996) Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex. Neuroscience 75:535

    Article  CAS  PubMed  Google Scholar 

  • Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K (1999) Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274:18438–18445

    Article  CAS  PubMed  Google Scholar 

  • Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117–154

    Article  CAS  PubMed  Google Scholar 

  • Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367–1377

    Article  CAS  PubMed  Google Scholar 

  • Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R et al (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331:574–590

    Article  CAS  PubMed  Google Scholar 

  • Hoffman DC, Donovan H (1994) D1 and D2 dopamine receptor antagonists reverse prepulse inhibition deficits in an animal model of schizophrenia. Psychopharmacology 115:447–453

    Article  CAS  PubMed  Google Scholar 

  • Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081–1090

    Article  CAS  PubMed  Google Scholar 

  • Kehler J, Nielsen J (2011) PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des 17:137–150

    Article  CAS  PubMed  Google Scholar 

  • Matamales M, Bertran-Gonzalez J, Salomon L, Degos B, Deniau JM, Valjent E et al (2009) Striatal medium-sized spiny neurons: identification by nuclear staining and study of neuronal subpopulations in BAC transgenic mice. PLoS One 4:e4770

    Article  PubMed Central  PubMed  Google Scholar 

  • McClure MM, Harvey PD, Goodman M, Triebwasser J, New A, Koenigsberg HW et al (2010) Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology 35:1356–1362

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev 5:660–670

    CAS  Google Scholar 

  • Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ (2007) Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 8:54–59

    CAS  PubMed  Google Scholar 

  • Natesan S, Reckless GE, Barlow KB, Odontiadis J, Nobrega JN, Baker GB et al (2008) The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology 199:275–289

    Article  CAS  PubMed  Google Scholar 

  • Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, Shuto T (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28:10460–10471

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Nishi A, Kuroiwa M, Shuto T (2011) Mechanisms for the modulation of dopamine D1 receptor signaling in striatal neurons. Front Neuroanat 5:1–10

    Google Scholar 

  • O’Donnell P, Grace AA (1998) Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr Bull 24:267–283

    Article  PubMed  Google Scholar 

  • Ouagazzal AM, Jenck F, Moreau JL (2001) Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? Psychopharmacology 156:273–283

    Article  CAS  PubMed  Google Scholar 

  • Peng RY, Mansbach RS, Braff DL, Geyer MA (1990) A D2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia. Neuropsychopharmacology 3:211–218

    Google Scholar 

  • Ralph RJ, Caine SB (2005) Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague–Dawley rats to Swiss–Webster, 129X1/SvJ, C57BL/6 J, and DBA/2 J mice. J Pharmacol Exp Ther 312:733–741

    Article  CAS  PubMed  Google Scholar 

  • Ralph-Williams RJ, Lehmann-Masten V, Otero-Corchon V, Low MJ, Geyer MA (2002) Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci 22:9604–9611

    CAS  PubMed  Google Scholar 

  • Roberts BM, Seymour PA, Schmidt CJ, Williams GV, Castner SA (2010) Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. Psychopharmacology 210:407–418

    Article  CAS  PubMed  Google Scholar 

  • Rodefer J, Murphy ER, Baxter MG (2005) PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21:1070–1076

    Article  PubMed  Google Scholar 

  • Sano H, Nagai Y, Miyakawa T, Shigemoto R, Yokoi M (2008) Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase10A2. J Neurochem 105:546–556

    Article  CAS  PubMed  Google Scholar 

  • Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF et al (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681–690

    Article  CAS  PubMed  Google Scholar 

  • Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL et al (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113–126

    Article  CAS  PubMed  Google Scholar 

  • Simpson EH, Kellendonk C, Kandel E (2010) A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65:585–596

    Article  CAS  PubMed  Google Scholar 

  • Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L et al (2006) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51:386–396

    Article  CAS  PubMed  Google Scholar 

  • Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, Vardigan JD et al (2013) The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology 64:215–223

    Article  CAS  PubMed  Google Scholar 

  • Sotty F, Montezinho LP, Steiniger-Brach B, Nielsen J (2009) Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to d-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons. J Neurochem 109:766–805

    Article  CAS  PubMed  Google Scholar 

  • Stevenson CW, Gratton A (2004) Role of basolateral amygdala dopamine in modulating prepulse inhibition and latent inhibition in the rat. Psychopharmacology 176:139–145

    Article  CAS  PubMed  Google Scholar 

  • Strick CA, James LC, Fox CB, Seeger TF, Menniti FS, Schmidt CJ (2010) Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A. Neuropharmacology 58:444–451

    Article  CAS  PubMed  Google Scholar 

  • Surmeier D, Ding J, Day M, Wang Z, Shen W (2007) D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30:228–235

    Article  CAS  PubMed  Google Scholar 

  • Swerdlow NR, Keith VA, Braff DL, Geyer MA (1991) Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J Pharmacol Exp Ther 256:530–536

    CAS  PubMed  Google Scholar 

  • Swerdlow NR, Shoemaker JM, Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL (2005) Reduced startle gating after D1 blockade: effects of concurrent D2 blockade. Pharmacol Biochem Behav 82:293–299

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Swerdlow NR, Shoemaker JM, Kuczenski R, Bongiovanni MJ, Neary AC, Tochen LS et al (2006) Forebrain D1 function and sensorimotor gating in rats: effects of D1 blockade, frontal lesions and dopamine denervation. Neurosci Lett 402:40–45

    Article  CAS  PubMed  Google Scholar 

  • Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL (2008) Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 199:331–388

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Wan FJ, Taaid N, Swerdlow NR (1996) Do D1/D2 interactions regulate prepulse inhibition in rats? Neuropsychopharmacology 14:265–274

    Article  CAS  PubMed  Google Scholar 

  • Weber M, Breier M, Ko D, Thangaraj N, Marzan DE, Swerdlow NR (2009) Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology 203:723–735

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Young JW, Powell SB, Geyer MA (2012) Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology 62:1381–1390

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank our collaborators Drs. Frank Menniti and Mark Geyer. We also thank Vince Quinn for technical assistance. The work presented here was supported by Pfizer Global Research and Development, Groton, CT and NIMH R01 MH042228-22A1.

Conflict of interest

The authors have nothing to disclose.

Author information

Author notes

  1. Patricia A. Seymour

    Present address: Mnemosyne Pharmaceuticals Inc., Providence, RI, USA

Authors and Affiliations

  1. Department of Psychiatry, University of California San Diego, La Jolla, CA, USA

    Jodi E. Gresack & Victoria B. Risbrough

  2. Neuroscience Research Unit, Pfizer Inc., Groton, CT, USA

    Patricia A. Seymour

  3. Neuroscience Research Unit, Pfizer Inc., Cambridge, MA, USA

    Christopher J. Schmidt

  4. Center of Excellence for Stress and Mental Health, Veterans Affairs Hospital, La Jolla, CA, USA

    Victoria B. Risbrough

  5. Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA

    Jodi E. Gresack

Authors
  1. Jodi E. Gresack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia A. Seymour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher J. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Victoria B. Risbrough
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jodi E. Gresack.

Additional information

The experiments described in this manuscript comply with the current U.S. laws on laboratory animal care.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 702 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gresack, J.E., Seymour, P.A., Schmidt, C.J. et al. Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating. Psychopharmacology 231, 2189–2197 (2014). https://doi.org/10.1007/s00213-013-3371-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-013-3371-7

Keywords

Search

Navigation